Rejected from Molecular Cell? The 7 Best Journals to Submit Next

• Molecular depth: Molecular Cell expects biochemical reconstitution, structural data (cryo-EM, crystallography, NMR), or detailed kinetic analysis. Cell biology experiments alone, even elegant ones, don't meet the bar unless they reveal molecular mechanism.

• Mechanistic completeness: Showing that protein X interacts with protein Y isn't enough. Molecular Cell wants to know the binding interface, the structural consequences, the downstream effects on the pathway, and the biological context. Partial mechanisms get desk-rejected.

• Biological significance beyond the molecule: The molecular mechanism must illuminate a biological process. A structural study of a protein with no known function, however beautiful, may not satisfy the editors unless the function is revealed alongside the structure.

• "The molecular mechanism is not sufficiently characterized.": You showed an interaction but didn't explain how it works. Molecular Cell wants binding domains, structural basis, and functional consequences.

• "The biological significance is unclear.": You solved a structure or characterized a pathway, but the connection to a biological process is weak. Molecular Cell needs both the molecule and the biology.

• "The work is primarily cell biology.": You used advanced imaging or cell biology techniques to show how a cellular process works, but the molecular mechanism driving the process isn't revealed. Molecular Cell wants the molecular explanation.

Before choosing your next journal, a Molecular Cell manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• Structural paper rejected?: NSMB first, then NAR (for nucleic acid structures) or PNAS (for protein structures).

• Gene regulation paper rejected?: EMBO Journal first, then NAR, then PNAS.

• Incomplete molecular mechanism?: Cell Reports (accepts partial stories) or Nature Communications (broad scope).

• Rejected after peer review?: Fix reviewer concerns. Then try EMBO Journal or NSMB, whose reviewer pools overlap with Molecular Cell.

EMBO Journal is the European counterpart to Molecular Cell. Both journals value mechanistic molecular biology with functional insight. The difference is editorial style: Molecular Cell follows the Cell Press comprehensive-story model, while EMBO Journal is sometimes more receptive to focused studies that reveal one clear molecular mechanism. EMBO Journal's transparent review process (referees see each other's reports) tends to produce balanced, constructive feedback. If your Molecular Cell experience involved an outlier harsh reviewer, EMBO's system mitigates that risk.

Best for: Molecular biology with functional implications, gene regulation, chromatin biology, RNA biology, and protein quality control.

If your paper's primary contribution is structural, NSMB is the most natural alternative. The journal publishes cryo-EM structures, crystallography, and integrative structural studies with a focus on biological mechanism. Where Molecular Cell expects the full biological story alongside the structure, NSMB is sometimes more receptive to structures that illuminate mechanism even without complete biological characterization.

Best for: Cryo-EM structures with mechanistic insight, structural biology of macromolecular complexes, structure-function relationships.

Cell Reports is the broad-scope Cell Press journal with a ~14% acceptance rate . For molecular biology papers that Molecular Cell found incomplete or too focused, Cell Reports accepts the work with what you have. The molecular bar is lower, and the biological story doesn't need to be fully connected.

Best for: Molecular biology papers with strong but incomplete mechanisms. Papers where Molecular Cell asked for structural or biochemical data you can't generate.

For papers focused on DNA biology, RNA biology, gene regulation, or chromatin, NAR is an excellent venue. The journal's scope aligns well with many Molecular Cell submissions, and the acceptance rate (~20%) is more accessible. NAR also publishes databases, computational tools, and resources for the nucleic acid research community. If your paper includes a new tool or resource alongside the biological finding, NAR values that dual contribution.

Best for: Gene regulation, RNA biology, DNA repair, chromatin biology, transcription mechanisms.

eLife publishes molecular mechanism papers with a commitment to open science and transparent review. The journal's "publish, then curate" model means your paper gets published with reviews attached, letting the community judge the work in context. For molecular biology papers where the mechanism is strong but the completeness doesn't meet Molecular Cell's standard, eLife's model may work in your favor: the reviews explain what's established and what's still open.

Best for: Molecular mechanism papers with strong but incomplete stories, papers where transparent review benefits the narrative.

PNAS publishes molecular biology across all areas and values rigor over narrative completeness. A focused biochemical study with clean data can succeed at PNAS even if the full biological story isn't connected. The journal is also strong for structural biology, protein engineering, and molecular evolution.

Best for: Focused molecular mechanism studies, structural biology, protein biochemistry, molecular evolution.

For molecular biology papers that are clearly good science but don't fit the specific editorial mandates of Molecular Cell or NSMB, Nature Communications provides a broad-scope home.

Best for: Solid molecular biology that fell below Molecular Cell's impact or completeness bar.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.

In our pre-submission review work with manuscripts targeting Molecular Cell, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Incomplete mechanistic characterization at the molecular level. Molecular Cell's editorial mandate is mechanistic completeness. We see this failure as the most common pattern in Molecular Cell desk rejections we review: papers identifying a new player in a pathway, demonstrating a phenotype, or showing a correlation between a molecular event and a biological outcome without fully characterizing the molecular mechanism. In our review of Molecular Cell submissions, we find that editors consistently require the causal mechanism, not just the observation.

Pathway biology without cross-system or physiological relevance. Molecular Cell expects that the mechanism revealed has implications beyond the specific experimental system studied. Papers characterizing a pathway in one cell line without in vivo validation, or in one species without functional conservation evidence, consistently receive concerns about the generalizability of the findings. Editors screen explicitly for whether the mechanism matters in a physiological or disease context.

Incremental advance on a well-characterized mechanism. Adding a new component to a pathway that is already extensively studied at Molecular Cell generates consistent desk rejection for limited advance. We see this pattern in submissions we review for Molecular Cell extend prior work from the same research group in the same pathway, with the new addition representing a single molecular player rather than a conceptual advance in understanding the mechanism.

Technology-driven papers without a biological discovery as the central contribution. Papers where the primary advance is a new biochemical method, structural technique, or genomic approach applied to a characterized system are consistently redirected to molecular methods-focused journals. Molecular Cell editors require that the biology discovered, not the approach used to discover it, be the central contribution.

SciRev community data for Molecular Cell confirms desk rejections typically arrive within days, with post-review first decisions in 6-8 weeks, consistent with the Cell Press editorial cadence.

Think twice before submitting to Cell or Nature Structural and Molecular Biology if the rejection reflected concerns about mechanistic completeness; those journals share Cell Press reviewer pools and the same gaps will resurface.